Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Company profile
Ticker
PSTV
Exchange
Website
CEO
Dr. Marc H. Hedrick M.B.A., M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Ault Global Holdings, Inc., BitNile Holdings, Inc., DIGITAL POWER CORP, DPW Holdings, Inc.
SEC CIK
Corporate docs
IRS number
330827593
PSTV stock data
Analyst ratings and price targets
Latest filings (excl ownership)
424B3
Prospectus supplement
6 Sep 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Sep 24
S-8
Registration of securities for employees
23 Aug 24
424B3
Prospectus supplement
15 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
15 Aug 24
424B3
Prospectus supplement
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
8-K
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
14 Aug 24
DEFA14A
Additional proxy soliciting materials
12 Jul 24
ARS
2023 FY
Annual report to shareholders
10 Jul 24
Transcripts
PSTV
Earnings call transcript
2024 Q2
14 Aug 24
PSTV
Earnings call transcript
2024 Q1
15 May 24
PSTV
Earnings call transcript
2023 Q4
5 Mar 24
PSTV
Earnings call transcript
2023 Q3
31 Oct 23
PSTV
Earnings call transcript
2023 Q2
14 Aug 23
PSTV
Earnings call transcript
2023 Q2
14 Aug 23
PSTV
Earnings call transcript
2023 Q1
20 Apr 23
PSTV
Earnings call transcript
2022 Q4
23 Feb 23
PSTV
Earnings call transcript
2022 Q3
21 Oct 22
PSTV
Earnings call transcript
2022 Q2
21 Jul 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.91 mm | 4.91 mm | 4.91 mm | 4.91 mm | 4.91 mm | 4.91 mm |
Cash burn (monthly) | (no burn) | 498.58 k | 1.23 mm | 1.18 mm | 383.33 k | 828.58 k |
Cash used (since last report) | n/a | 1.35 mm | 3.34 mm | 3.19 mm | 1.04 mm | 2.25 mm |
Cash remaining | n/a | 3.56 mm | 1.57 mm | 1.73 mm | 3.87 mm | 2.67 mm |
Runway (months of cash) | n/a | 7.1 | 1.3 | 1.5 | 10.1 | 3.2 |
Institutional ownership, Q1 2024
9.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 781.00 k |
Total shares | 530.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 300.00 k | $315.00 k |
NanoTx | 230.77 k | $466.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Sep 24 | Hawkins Richard J | Common Stock | Buy | Acquire P | No | No | 1.499 | 4,000 | 6.00 k | 15,188 |
12 Sep 24 | Hawkins Richard J | Common Stock | Buy | Acquire P | No | No | 1.3543 | 6,285 | 8.51 k | 11,188 |
11 Sep 24 | van Es-Johansson An | Stock Option Common Stock | Grant | Acquire A | No | No | 1.26 | 3,650 | 4.60 k | 3,650 |
11 Sep 24 | Robert P Lenk | Stock Option Common Stock | Grant | Acquire A | No | No | 1.26 | 3,650 | 4.60 k | 3,650 |
11 Sep 24 | Howard Clowes | Stock Option Common Stock | Grant | Acquire A | No | No | 1.26 | 3,650 | 4.60 k | 3,650 |
News
Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $20
3 Sep 24
HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
16 Aug 24
Plus Therapeutics Q2 2024 Adj EPS $(0.71) Misses $(0.53) Estimate
14 Aug 24
Plus Therapeutics Q2 Sales $1.28M Miss $1.68M Estimate
14 Aug 24
Plus Therapeutics Says CNSide Leptomeningeal Metastases FORSEE Trial Met Key Primary And Secondary Endpoints
13 Aug 24
Press releases
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
18 Sep 24
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
4 Sep 24
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
14 Aug 24
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
13 Aug 24
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
12 Aug 24